JFL Life Sciences Limited

NSEI:JFLLIFE Stok Raporu

Piyasa değeri: ₹768.8m

JFL Life Sciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

JFL Life Sciences has been growing earnings at an average annual rate of 30%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 9.6% per year. JFL Life Sciences's return on equity is 9.3%, and it has net margins of 7.1%.

Anahtar bilgiler

30.0%

Kazanç büyüme oranı

21.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi17.5%
Gelir büyüme oranı9.6%
Özkaynak getirisi9.3%
Net Marj7.1%
Son Kazanç Güncellemesi31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding JFL Life Sciences Limited's (NSE:JFLLIFE) Performance Completely

Sep 17
Even With A 27% Surge, Cautious Investors Are Not Rewarding JFL Life Sciences Limited's (NSE:JFLLIFE) Performance Completely

Further Upside For JFL Life Sciences Limited (NSE:JFLLIFE) Shares Could Introduce Price Risks After 27% Bounce

Jul 05
Further Upside For JFL Life Sciences Limited (NSE:JFLLIFE) Shares Could Introduce Price Risks After 27% Bounce

Gelir ve Gider Dağılımı

JFL Life Sciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NSEI:JFLLIFE Gelir, gider ve kazançlar (INR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 2446633200
31 Dec 2345432220
30 Sep 2344331240
30 Jun 2343630210
31 Mar 2342828180
31 Dec 2244828160
30 Sep 2246827130
30 Jun 2240228140
31 Mar 2233628140
28 Feb 2227228110
31 Mar 213285100
31 Mar 203024130
31 Mar 193183100

Kaliteli Kazançlar: JFLLIFE has high quality earnings.

Büyüyen Kar Marjı: JFLLIFE's current net profit margins (7.1%) are higher than last year (6.6%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: JFLLIFE's earnings have grown significantly by 30% per year over the past 5 years.

Büyüme Hızlandırma: JFLLIFE's earnings growth over the past year (17.8%) is below its 5-year average (30% per year).

Kazançlar vs. Sektör: JFLLIFE earnings growth over the past year (17.8%) did not outperform the Pharmaceuticals industry 19.1%.


Özkaynak Getirisi

Yüksek ROE: JFLLIFE's Return on Equity (9.3%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin